Table 3.
Comparison of RECIST best response with best CTN/CEA response and RET germline mutation status
| Patienta | Best tumor response (largest percent change in tumor size) | Best CTN response (percent change from baseline)b | Best CEA response (percent change from baseline)b | RET germline mutationc |
|---|---|---|---|---|
| 1 | Confirmed PR (−54.0) | SD (−42.3) | SD (−16.4) | C380R |
| 2 | Confirmed PR (−40.0) | PR (−89.4) | SD (−83.7) | E768D |
| 3 | Confirmed PR (−33.3) | SD (−43.0) | SD (+4.4) | C634R |
| 4 | SD ≥ 24 wk (−28.1) | PR (−66.8) | SD (−28.0) | C634R |
| 5 | SD ≥ 24 wk (−21.4) | SD (−36.8) | SD (−24.6) | C620R |
| 6 | SD ≥ 24 wk (−20.0) | SD (−24.6) | SD (−32.4) | C634L |
| 7 | SD ≥ 24 wk (−18.8) | SD (+7.1) | PD (+72.0) | C618S |
| 8 | SD ≥ 24 wk (−9.5) | SD (−9.7) | SD (−9.63) | NE |
| 9 | SD ≥ 24 wk (−1) | SD (−37.0) | SD (+4.7) | C620R |
| 10 | SD ≥ 24 wk (0) | SD (−31.8) | SD (−6.9) | M918T |
| 11 | SD ≥ 24 wk (0) | SD (−45.8) | SD (−25.1) | C634R |
| 12 | SD ≥ 24 wk (0) | SD (−27.8) | SD (−10.4) | C634Y |
| 13 | SD ≥ 24 wk (0) | PR (−65.4) | PR (−62.1) | C634R |
| 14 | SD ≥ 8 wk, <24 wk (−18.2) | SD (−15.7) | SD (−37.8) | C608S |
| 15 | SD ≥ 8 wk, <24 wk (−3.2) | SD (−1.4) | SD (−32.9) | NE |
| 16 | PD (+17.2) | SD (+3.2) | SD (+26.2) | C618S |
| 17 | PD (+20.3) | PD (+57.0) | SD (+44.2) | C634R |
| 18 | PD (+28.1) | PD (+64.0) | SD (+37.6) | C634R |
NE, Not evaluable; PR, partial response; SD, stable disease.
a
One patient not evaluable for objective response (RECIST).
b
CTN and CEA response criteria: PR, 50% or greater decrease from baseline levels maintained over a minimum of 4 wk; SD, between +50% and −50% change from baseline levels maintained over a minimum of 4 wk.
c
Codon and amino acid substitution.